Mineralys CCO sells 7,438 shares after option exercise

Available on EDGAR 09/22/2026 - 06:49 PM EDT Accepted by SEC EDGAR 09/22/2026 - 06:48 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. (MLYS) reported that Chief Commercial Officer Warren Eric exercised stock options for 7,438 shares of common stock on September 21, 2026 at an exercise price of $13.24 per share and sold the same 7,438 shares at a weighted-average price of $28.1172 per share. These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026. Following the option exercise, Eric held 230,563 stock options directly, expiring on April 21, 2035, subject to the stated vesting schedule.

Insider Trade Summary 10b5-1

Exercise and Sale: 7,438 shares ($111K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Warren Eric

Role Chief Commercial Officer

Sold 7,438 shs ($209K)

Approx. gross sale proceeds $209K

Approx. exercise cost $98K

Approx. pre-tax spread $111K

Share of Position Sold 16.2%

Type	Security	Shares	Price	Value
Exercise	Stock Option F1, F3	7,438	$0.00	$0.00
Exercise	Common Stock F1	7,438	$13.24	$98K
Sale	Common Stock F1, F2	7,438	$28.1172	$209K

Holdings After Transaction: Stock Option — 230,563 options (Direct); Common Stock — 38,400 shares (Direct)

Holdings Before and After: Stock Option, 238,001 to 230,563 options (Direct); Common Stock, 38,400 to 38,400 shares (Direct)

Other Insiders: 1 other insider reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (3)

1. F1. These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.
2. F2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.94 to $28.21. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
3. F3. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

Key Figures

Shares sold: 7,438 shares Weighted-average sale price: $28.1172 per share Option exercise price: $13.24 per share +5 more

8 metrics

Shares sold 7,438 shares Common stock sold by Warren Eric on September 21, 2026

Weighted-average sale price $28.1172 per share Sale of 7,438 shares of common stock; individual prices $27.94–$28.21

Option exercise price $13.24 per share Exercise of stock option for 7,438 underlying shares of common stock

Options exercised 7,438 options Stock options converted into 7,438 shares of common stock on September 21, 2026

Remaining stock options 230,563 options Stock options held directly by Warren Eric following the reported transactions

Option expiration date April 21, 2035 Expiration of the stock option that was partially exercised

Rule 10b5-1 plan adoption date March 27, 2026 Date the stock selling plan governing these transactions was adopted

Sale price range $27.94–$28.21 per share Range of prices for the multiple transactions included in the weighted-average sale

Key Terms

Rule 10b5-1 stock selling plan, weighted-average price, stock option, underlying shares

4 terms

Rule 10b5-1 stock selling plan regulatory

"These transactions were effected pursuant to a Rule 10b5-1 stock selling plan"

weighted-average price financial

"The price reported in Column 4 is a weighted-average price."

Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.

stock option financial

"The stock option vested as to 25% of the underlying shares"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

underlying shares financial

"25% of the underlying shares on the first anniversary"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Mineralys Therapeutics (MLYS) disclose about Warren Eric’s recent Form 4 transactions?

The company reported that Chief Commercial Officer Warren Eric exercised options for 7,438 shares of common stock at $13.24 per share and sold the same 7,438 shares at a weighted-average price of $28.1172 per share on September 21, 2026.

How many Mineralys Therapeutics (MLYS) shares did Warren Eric sell and at what price?

He sold 7,438 shares of Mineralys Therapeutics common stock at a weighted-average price of $28.1172 per share, with individual sale prices ranging from $27.94 to $28.21, as disclosed in the Form 4 footnote.

Were Warren Eric’s MLYS trades made under a Rule 10b5-1 trading plan?

Yes. The Form 4 states that the reported transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026, indicating they were pre-arranged under that plan.

What was the exercise price and type of security for Warren Eric’s Mineralys options?

He exercised a stock option covering 7,438 underlying shares of Mineralys common stock at an exercise price of $13.24 per share. The option expires on April 21, 2035, with vesting over time per the disclosed schedule.

How many Mineralys Therapeutics stock options does Warren Eric hold after these transactions?

After the reported option exercise, Warren Eric held 230,563 stock options directly, as reported in the Form 4, representing his remaining derivative position from this grant.

What is the vesting schedule for Warren Eric’s Mineralys stock option mentioned in the Form 4?

The filing states the stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Warren Eric

(Last) (First) (Middle)

150 N. RADNOR CHESTER ROAD

SUITE F200

(Street)

RADNOR PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/21/2026		M(1)		7,438	A	$13.24	45,838	D
Common Stock	09/21/2026		S(1)		7,438	D	$28.1172(2)	38,400	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$13.24	09/21/2026		M(1)			7,438	(3)	04/21/2035	Common Stock	7,438	$0	230,563	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.

2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.94 to $28.21. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

3. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

Remarks:

	/s/ Adam Levy, Attorney-in-fact	09/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)